Table 2.
Rheumatological status of SpA patients.
| SpA n = 37 |
||
|---|---|---|
| n | % | |
| ASAS criteria | ||
| Axial | 33 | 89.2 |
| Peripheral | 4 | 10.8 |
| SpA symptoms | ||
| Inflammatory low back pain | 34 | 91.9 |
| Mechanical low back pain | 7 | 18.9 |
| Dactylitis | 7 | 18.9 |
| Enthesitis | 29 | 78.4 |
| Arthritis | 27 | 73.0 |
| Fatigue | 30 | 81.1 |
| Treatment | ||
| Biological | 25 | 67.6 |
| Type of treatment | ||
| Anti-IL17 | 3 | 12.0 |
| Anti-TNF | 22 | 88.0 |
| CRP ** | 0.78 (0.28–2.24) | |
| >3 mg/L | 5 | 13.5 |
| ESR | 4.5 (2.6–7.3) | |
| Faster-than-normal rate | 20 | 54.1 |
| HLA B27 positive | 15 | 40.5 |
| BASFI ** | 5.0 (3.2–7.1) | |
| BASFI > 4 | 22 | 59.5 |
| BASDAI ** | 2.6 (2.2–3.0) | |
| BASDAI > 4 | 29 | 78.4 |
| ASDAS-CRP ** | 2.6 (2.2–3.0) | |
| ASDAS-CRP > 2.1 | 29 | 78.4 |
| ASDAS-CRP > 3.5 | 5 | 13.5 |
| ASDAS-ESR ** | 2.8 (2.3–3.5) | |
| ASDAS-ESR > 2.1 | 31 | 83.8 |
| ASDAS-ESR > 3.5 | 10 | 27.0 |
** Results are expressed in medians (IQR). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; HLA: human leukocyte antigen.